In vitro studies on the immunosuppressive effect of 2′,2′-difluorodeoxycytidine (dFdC) and its metabolite 2′,2′-difluorodeoxyuridine (dFdU)

Immunobiology

Volumn 207, Issue 2, 2003, Pages 149-157

  Tiefenthaler, Martin ^a   Hohla, Florian ^a   Irschick, Eveline ^a   Strasser Wozak, Elisabeth ^a   Bacher, Nicole ^a   Mühlmann, Oliver ^a   Wein, Wolfgang ^b   Konwalinka, Günther ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b ELI LILLY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2',2' DIFLUORODEOXYURIDINE; ALLOANTIGEN; CD34 ANTIGEN; CORTICOSTEROID; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DEOXYURIDINE DERIVATIVE; DEXAMETHASONE; DRUG METABOLITE; GEMCITABINE; GLUCOCORTICOID; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; METHYLCELLULOSE; MITOGENIC AGENT; PHYTOHEMAGGLUTININ; UNCLASSIFIED DRUG;

CELL ASSAY; CELL CLONING; CELL GROWTH; CELL STRAIN HL 60; COLONY FORMATION; COLONY FORMING UNIT GM; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DATA ANALYSIS; DOSE RESPONSE; DRUG ACTIVATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; ERYTHROID PRECURSOR CELL; HUMAN; HUMAN CELL; IC 50; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LETHALITY; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION; MIXED LYMPHOCYTE REACTION; MONONUCLEAR CELL; PRIORITY JOURNAL; PROMYELOCYTE; REVIEW; SENSITIVITY ANALYSIS; T LYMPHOCYTE; VOLUNTEER;

EID: 0037240743     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1078/0171-2985-00223     Document Type: Review

References (16)

1. Abbruzze JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN and Plunkett W. 1991. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J. Clin. Oncol. 9: 491-498.
2. Bergman AM, Pinedo HM and Peters GJ. 2001. Steroids affect collateral sensitivity to gemcitabine of multi-drug-resistant human lung cancer cells. Eur. J. Pharmacol. 416; 19-24.
3. Braakhuis BJ, van Dongen GA, Vermorken JB and Snow GB. Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (gemcitabine) against head and neck cancer. 1991. Cancer Res. 51: 211-214.
4. Campling G, Pym J, Galbrighth PR and Cole SP. 1988. Use of the MTT assay for rapid determination of chemosensitivity of human leukemic blast cells. Leuk. Res. 12: 823-831.
5. Gorski A, Grieb P, Makula J, Stepien-Sopniewska B, Mrowiec T and Nowaczyk M. 1993. 2-Chloro-2-deoxyadenosine: a novel immunosuppressive agent. Transplantation. 56: 1253-1257.
6. Grunewald R, Abbruzze JL, Tarassoff P and Plunkett W. 1991. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemoth. Pharmacol. 27: 258-262.
7. Heinemann V, Hertel LW, Grindey GB and Plunkett W. 1988. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 48: 4024-4031.
8. Heinemann V, Xu Y-Z, Chubb S, Sen A, Hertel LW, Grindey GB and Plunkett W. 1990. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2-difluorodeoxycytidine. Mol. Pharmacol. 38: 567-572.
9. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC and Grindey GB. 1990. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res. 50: 4417-4422.
10. Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W. 1991. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51: 6110-6117.
11. Margreiter R, Fischer M, Roberts K, Schmid T, Hittmair A, Schirmer M, Geisen F, Tiefenthaler M and Konwalinka G. 1999. Gemcitabine - a novel immunosuppressive agent-prevents rejection in a rat cardiac transplantation model. Transplant. 68: 1051-1063.
12. Nachbauer D, Fink FM, Nussbaumer W, Gachter A, Kropshofer G, Ludescher C and Niederwieser D. 1997. CD34+selected autologous peripheral stem cell transplantation (PBSCT) in patients with poor risk hematological malignancies and solid tumors. A single center experience. Bone Marrow Transplantation. 20: 827-834.
13. Petzer AL, Bilgeri R, Zilian U, Haun M, Geisen F.H, Pragnell I, Braunsteiner H and Konwalinka G. 1991. Inhibitory effect of 2-chloro-2-deoxyadenosine in granulocytic, erythroid, and T-lymphocytic colony growth. Blood. 78: 2583-2587.
14. Plunkett W, Gandhi V, Chubb S, Novak B, Heinemann V, Mineishi S, Sen A, Hertel LW and Grindey GB. 1989. 2′,2′-difluorodeoxycytidine metabolism and mechanism of action in human leukemia cells. Nucleosides Nucleotides. 8: 775-785.
15. Rieger J, Durka S, Streffer J and Weller M. 1999 Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, bcl-2 and dexamethasone. Eur. J. Pharamacol. 365: 301-308.
16. Zier KS, Huber CH and Braunsteiner H. Linear density gradient separation of human lymphocyte subsets. 1977. Analysis by mixed leukocyte culture and cell mediated lympholysis responses. Eur. J. Immunol. 7: 366-370.